Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Chimerix Inc.
Sponsor

Chimerix Inc.

United States 2505 Meridian Parkway Suite 340, 27713-5247, United States

About the sponsor

Chimerix Inc. focuses on clinical research in H3 K27M-mutant diffuse glioma, a molecularly defined form of brain cancer within the field of central nervous system oncology.

  • Diffuse glioma
  • H3 K27M mutation
  • Malignant glioma

The sponsor’s active trial landscape is centered on treatment after radiotherapy for this aggressive glioma subtype, with research activity extending across multiple collaborating sites in several countries.

About Specializations

Chimerix Inc. runs clinical trials in conditions such as Malignant glioma, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

1 clinical trial

Malignant glioma

Recruiting
Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:2,4,6,7,8,9-Hexahydro-4-((2-Methylphenyl)Methyl)-7-(Phenylmethyl)Imidazo(1,2-A)Pyrido(3,4-E)Pyrimidin-5(1H)-One
  • Sponsor:Chimerix Inc.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.